You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AIN457

Showing 1 - 25 of 117
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Polymyalgia Rheumatica Trial (Secukinumab 300 mg, Secukinumab 150 mg, Placebo to secukinumab)

Not yet recruiting
  • Polymyalgia Rheumatica
  • Secukinumab 300 mg
  • +2 more
  • (no location specified)
Mar 6, 2023

Tendinopathy Trial in Germany (secukinumab, Placebo)

Recruiting
  • Tendinopathy
  • Berlin, Germany
  • +7 more
Jan 5, 2023

Giant Cell Arteritis, Polymyalgia Rheumatica Trial (Secukinumab)

Not yet recruiting
  • Giant Cell Arteritis
  • Polymyalgia Rheumatica
  • (no location specified)
Nov 8, 2023

Rotator Cuff Tendinopathy Trial (Secukinumab, Placebo)

Not yet recruiting
  • Rotator Cuff Tendinopathy
  • (no location specified)
Feb 24, 2023

Rotator Cuff Tendinopathy Trial (Secukinumab, Placebo)

Not yet recruiting
  • Rotator Cuff Tendinopathy
  • (no location specified)
Feb 1, 2023

Ankylosing Spondylitis (AS) Trial in Wuhan (Secukinumab 300mg s.c., Secukinumab 150mg s.c.)

Recruiting
  • Ankylosing Spondylitis (AS)
  • Secukinumab 300mg s.c.
  • Secukinumab 150mg s.c.
  • Wuhan, Hubei, China
  • +2 more
Mar 20, 2022

Tendinopathy Trial in Worldwide (secukinumab, Placebo)

Completed
Has Results
  • Tendinopathy
  • Phoenix, Arizona
  • +11 more
Oct 7, 2021

Psoriatic Arthritis Trial in Germany, Netherlands, United Kingdom (AIN457A, Other)

Completed
Has Results
  • Psoriatic Arthritis
  • AIN457A
  • Other
  • Hamburg, Germany
  • +5 more
May 26, 2021

Polymyalgia Rheumatica, Inflammatory Diseases Trial in Worldwide (AIN457, ACZ885, Prednisone)

Terminated
Has Results
  • Polymyalgia Rheumatica
  • Inflammatory Diseases
  • AIN457
  • +3 more
  • Rochester, Minnesota
  • +5 more
Aug 17, 2021

Giant Cell Arteritis Trial in Germany (Secukinumab 300 mg, s.c., Prednisolone, Placebo)

Completed
  • Giant Cell Arteritis
  • Secukinumab 300 mg, s.c.
  • +2 more
  • Berlin, Germany
  • +10 more
Feb 25, 2022

Crohn's Disease, Inflammatory Bowel Disease Trial in United States (AIN457)

Terminated
Has Results
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • AIN457
  • Bristol, Connecticut
  • +4 more
Jun 18, 2021

Lupus Nephritis Trial (Secukinumab)

Recruiting
  • Lupus Nephritis
  • Westmead, New South Wales, Australia
  • +4 more
Oct 19, 2022

Plaque Psoriasis, Non-alcoholic Fatty Liver Disease Trial in Germany, Spain (Investigational Arm - secukinumab, Control Arm - )

Completed
  • Plaque Psoriasis
  • Non-alcoholic Fatty Liver Disease
  • Investigational Arm - secukinumab
  • Control Arm - placebo
  • Erlangen, Germany
  • +7 more
Jan 12, 2022

Giant Cell Arteritis Trial (Secukinumab 300 mg, s.c., Placebo to match Secukinumab, s.c.)

Recruiting
  • Giant Cell Arteritis
  • Secukinumab 300 mg, s.c.
  • Placebo to match Secukinumab, s.c.
  • Berlin, Germany
  • +2 more
Oct 12, 2022

Moderate to Severe Chronic Plaque-type Psoriasis Trial in Worldwide (secukinumab low dose, secukinumab high dose)

Active, not recruiting
Has Results
  • Moderate to Severe Chronic Plaque-type Psoriasis
  • secukinumab low dose
  • secukinumab high dose
  • Fountain Valley, California
  • +22 more
Dec 24, 2022

Healthy, Psoriasis Trial in Graz (secukinumab (AIN457))

Completed
  • Healthy
  • Psoriasis
  • secukinumab (AIN457)
  • Graz, Austria
    Novartis Investigative Site
Dec 6, 2020

Non-radiographic Axial Spondyloarthritis Trial in China (Secukinumab, Placebo)

Recruiting
  • Non-radiographic Axial Spondyloarthritis
  • Hefei, Anhui, China
  • +35 more
Oct 14, 2022

Ankylosing Spondylitis Trial in Germany (Secukinumab (AIN457) 150 mg s.c., Placebo - Secukinumab (AIN457) 150 mg s.c.)

Completed
Has Results
  • Ankylosing Spondylitis
  • Secukinumab (AIN457) 150 mg s.c.
  • Placebo - Secukinumab (AIN457) 150 mg s.c.
  • Bad Doberan, Germany
  • +38 more
Oct 7, 2021

Thyroid Eye Disease, Graves Orbitopathy Trial in Germany (Secukinumab, Placebo)

Recruiting
  • Thyroid Eye Disease
  • Graves Orbitopathy
  • Essen, Germany
  • +6 more
Jul 14, 2022

Psoriasis Trial (Secukinumab 300 mg, Placebo)

Withdrawn
  • Psoriasis
  • Secukinumab 300 mg
  • Placebo
  • (no location specified)
Jan 30, 2022

Uveitis Trial in Worldwide (AIN457, Placebo)

Withdrawn
  • Uveitis
  • AIN457
  • Placebo
  • Arlington, Texas
  • +10 more
Sep 24, 2020

Chronic Severe Plaque-type Psoriasis Trial in Worldwide (Experimental : Secukinumab low dose, Experimental: Secukinumab high

Active, not recruiting
Has Results
  • Chronic Severe Plaque-type Psoriasis
  • Experimental : Secukinumab low dose
  • +3 more
  • San Antonio, Texas
  • +45 more
Jan 30, 2022

Ankylosing Spondylitis Trial in United States (150 mg open-label secukinumab, 150 mg double-blinded secukinumab, 300 mg

Completed
Has Results
  • Ankylosing Spondylitis
  • 150 mg open-label secukinumab
  • +2 more
  • Jonesboro, Arkansas
  • +64 more
Apr 27, 2022

Colorectal Cancer Trial (SHR-1210, AIN 457)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Mar 12, 2020

Psoriatic Arthritis Trial in China (Secukinumab (AIN457), Secukinumab Placebo)

Recruiting
  • Psoriatic Arthritis
  • Secukinumab (AIN457)
  • Secukinumab Placebo
  • Chongqing, Chongqing, China
  • +14 more
Dec 2, 2021